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hospitalisation, and the modified Rankin Scale (mRS), the most frequently used 
outcome measure in stroke trials. Methods: Data from all ischemic stroke hos-
pitalizations from a teaching hospital in Belgium were collected between 2006 and 
2009. Data collection included the SOI, patient characteristics (age, gender), risk 
factors (hypertension, smoking, hypercholersterolemia, diabetes, CAD, PAD, previ-
ous stroke), clinical parameters (aorta-atherosclerosis, cancer, TOAST (large-artery 
atherosclerosis, cardioembolism, small-vessel occlusion, other), microbleeds, atrial 
fibrillation, akinesiahypokinesa, endocarditis, MI), functional scales (NiH, mRS), 
repeat events. An ordered multinomial regression estimated the relationship 
between the SOI and these covariates. Using the regression parameters and the 
mean value of the other covariates, predicted values were generated for each com-
bination of the mRS and the SOI. Monte Carlo simulations generated a set of pre-
dicted SOI values per patient (response mapping). Data from 2010 and 2011 were 
used for validation of the regression model. Results: 559 hospitalizations were 
used for the regression analysis. Factors that were discriminating in predicting the 
correct SOI category were the mRS (p< 0.001), age (p= 0.0017), NIH at arrival in hos-
pital (p< 0.001), TOAST (p= 0.0129), atrial fibrillation (0.0217) and repeat in-hospital 
event (p= 0.0031). Generating Monte Carlo predicted values demonstrated good 
concordance across SOI levels at the population level (2.3% vs 2.0% categorized 
in SOI1, 49.8% vs 50.3% in SOI2, 32.9% vs 31.4% in SOI3, 15.4% vs 16.0% in SOI4, for 
the true and the simulated proportions respectively), and the root mean-squared 
error was 0.33. Validation of the data with 588 hospitalizations from 2010 and 2011 
confirmed the good fit of the model. ConClusions: Factors affecting the reim-
bursement/payment level of a stroke admission are age, location of the ischemia, 
atrial fibrillation, scores on stroke functional scales and new in-hospital events.
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objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. Thus, this study was designed to identify epidemiological 
data, screening and treatment guidelines, costs as well as outcome of intravenous 
iron treatment in patients with CHF and iron deficiency. Methods: A comprehen-
sive literature review was undertaken for all publications from 1998 to September 
2014 using Medline, EMBASE, Cochrane, Science Direct and Pubmed databases, 
comprising English and German articles. The review focused on studies based on 
patients with chronic heart failure and iron deficiency, with or without anemia. 
Articles were systematically selected if they included data for iron deficiency on 
at least one of the following criteria: epidemiology, screening and treatment guide-
lines, costs, clinical outcomes. Results: Database search yielded 5,132 articles 
and 55 additional articles were identified via secondary hand searches. Of the 73 
eligible articles; 30 provided information on epidemiological data, 14 on screening 
and treatment guidelines, 15 on costs and 14 on clinical outcomes. The prevalence 
of CHF ranges between 0.88-6.4%. Out of these, 8-53% suffer from iron deficiency 
depending on the disease severity (New York Heart Association classes - NYHA) 
of heart failure. According to the ESC Guidelines 2012 intravenous iron may be 
considered to improve symptoms, quality of life and exercise capacity based on 
the data of FCM (FAIR-HF, CONFIRM-HF–based on 456 patients). Considering the 
included studies of this review, healthcare expenditure on CHF consumes 1-2% of 
the total healthcare budget. CHF patients with ID induce higher healthcare costs 
compared to non-iron deficient patients (+24%). ConClusions: CHF represents 
a major and growing public health problem and is often associated with ID as 
co-morbidity. IV iron can be an option to improve outcome (patient status), and 
reduce health care costs.
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objeCtives: One of the main modifiable risk factors is the blood lipid levels, due 
to changes in lifestyle and treatment. The aim of this study is to characterize total 
cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein 
cholesterol (HDL-C) levels in adults with hypertension, diabetes, HT and DM, and 
CKD, reported to Cuenta de Alto Costo, 2014. Methods: Descriptive and retrospec-
tive study. The information was obtained from the medical records of approx. 53 
health insurance companies in Colombia. Data from 2.995.061 patients was used. 
Stata 13 was used for data analysis. Qualitative variables were described by its 
frequency distribution. Results: 73% of patients had diagnosis of HT, 6,7% of DM, 
19,6% of HT and DM, and 30% had CKD. In the population with HT, 30,6% had TC 
levels in upper limits and 16,4% in a high level. In patients with DM, 54,3% had 
desirable levels. In patients with both diseases, 25,5% had TC levels in upper limits 
and 14,1% in a high level. In CKD patients, 15% had high level of TC. Regarding HDL 
levels, 56,2% HT patients had HDL levels between 40-60mg/dl. Near 36,1% of DM 
patients had low HDL levels (< 40mg/dl), patients with both diseases had similar 
levels (33,5%). Optimum LDL levels were identified in 42,8% of patients with both 
diseases (HT and DM), in contrast with 32,8% and 35% HTA and DM patients respec-
tively. Around 9% of both diseases had high LDL levels and 4% had very high LDL 
levels. 54% of CKD patients had HDL levels between 40-60mg/dl and 27,8% had 
HDL levels under 40mg/dl. In CKD patients we found that 8,3% had high LDL-C 
levels. ConClusions: patients with both diseases (HT and DM) had better LDL and 
TC levels than patients with other diseases, however HDL-C levels under 40mg/dl 
were higher in this patients group.
this disease. Methods: Network Meta Analysis using Winbugs (Bayesian, Markov 
chain model using dedicated software), which allows to make an informed decision 
on the clinical effectveness ranking of some of the healthcare technologies (active 
substances) used in the treatment of Pulmonary Arterial Hypertension (PAH). The 
ranking is then compared with the ICER, currently in use by UK NICE and the treat-
ment guidelines set by the UK NHS. Results: Usug the above methods, the ranking 
of healthcare technologies (active substances) used in PAH has been establihed 
and different scenarios have been identified, with regard to increasing efficiency 
of public healthcare expenditure on PAH. ConClusions: The various scenarios 
proposed in this analysis, once confirmed, will contribute to a gain in efficency of 
public healthcare expenditure on PAH in the UK.
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objeCtives: Cardiovascular diseases are the leading cause of death and disability 
in the population of most countries, including Ukraine. Ukraine faces a significant 
contribution of cardiovascular diseases in the formation of disability-adjusted life 
year (DALY): men – for 27%, women – for 33% (2013). Methods: At the end of 
2014 the multidisciplinary working groups on the development of guidelines and 
protocols on different areas of cardiovascular diseases were approved. According 
to the results of a systematic literature review conducted in the databases Medline, 
PubMed, DynaMed, G-I-N etc. ESC, ACCF/AHA and NICE guidelines were selected 
for adaptation in Ukraine. Results: During the meetings the working groups dis-
cussed the opportunities to meet the guidelines’ recommendations in real condi-
tions in Ukraine. For example, there were debates concerning mandatory evaluation 
of highly sensitive troponin on the 99th percentile among patients with NSTEMI, 
or the appointment of new antiplatelet drugs with high evidence base, which were 
not registered in Ukraine at this stage (eg. Prasugrel or Argatroban). The adapted 
guidelines for the treatment of acute and chronic coronary artery disease included 
separate sections with recommendations for revascularization from 2014 ACCF/AHA 
guideline, which allows the doctor to stratify patient against the risk of complica-
tions and identify high-risk patients who should be enforced urgent percutaneous 
coronary intervention. As a result of the work there will be prepared adapted clinical 
guidelines and unified clinical protocols on Acute Coronary Syndromes Without 
ST Segment Elevation, Stable Coronary Artery Disease, Pulmonary Hypertension, 
Prevention of Cardiovascular Disease, Dyslipidemia, Heart Failure, and Atrial 
Fibrillation. ConClusions: Development of medical and technological documents 
on standardization of medical care in cardiovascular diseases will allow to harmo-
nize Ukrainian practice with international recommendations and timely provide 
quality medical care for the relevant areas.
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objeCtives: To describe and analyze heart failure (HF) patients, disease path-
way and related healthcare resource use and expenditures in France. Methods: 
Analysis was based on EGB (“Echantillon Généraliste des Bénéficiaires”) database, 
a permanent random sample (1/97) of the French national healthcare insurance 
system database (SNIIRAM), linked with the national hospital discharge summary 
database (PMSI). Patients were selected on the following criteria: HF classified 
as long-term disease (ALD scheme) in 2012 and/or at least 1 HF hospitalization 
(ICD-10 codes) on 2008-2012 period and/or at least 3 reimbursements of HF rec-
ommended drugs (including beta-blockers (BB), angiotensin-converting-enzyme 
inhibitors (ACEi), angiotensin-receptor-blockers (ARB), diuretics, digoxin, ivabradine) 
in 2012. Results: 12,981 patients (average age: 74.8 years; 51.6% of men) were 
included, representing a HF prevalence of 2.2% in the total French population. Most 
of patients visited a general practitioner (93.1%) on regular basis (9.3 visits/year), but 
only few of them visited a cardiologist (37.0%) through the year (0.67 visit/year). HF 
recommended drugs were not prescribed to all patients (BB: 60.3%; ACEi/ARB: 53,3%; 
diuretics: 46.0%) and the recommended triple therapy (BB+ACEi/ARB+diuretics) was 
prescribed to only few of them (16.4%). Almost half of patients (47.3%) were hospital-
ized within the year (1.3 hospitalizations/year), with a quarter of these hospital stays 
related to HF (27.0%). The annual age-standardized mortality rate was 4.6 higher 
than in the full EGB database (939.0 versus 71.1 per 10,000 persons). Annual aver-
age healthcare costs were 7,956€ /patient, mostly driven by hospitalizations (3,683€ ; 
46,3%), drugs (1,287€ ; 16,2%), paramedical visits (980€ ; 12,3%) and medical visits 
(464€ ; 5,8%). ConClusions: Patients are not optimally managed for their HF, with 
a limited healthcare resource use. Despite a high rate of hospitalization, cardiologist 
visits remain at a very low frequency in this HF population. Better referring these 
patients to cardiologists should improve their management and optimize drugs 
prescription as recommanded in the guidelines.
PCV178
InVestIgatIng the relatIonshIP betWeen “seVerIty of Illness” anD 
the “moDIfIeD ranKIn sCale” In IsChemIC stroKe PatIents WIth 
resPonse maPPIng
Dewilde S1, Annemans L2, Thijs V3
1SHE & UGent, Brussel, Belgium, 2University of Ghent, Ghent, Belgium, 3KULeuven, Leuven, 
Belgium
objeCtives: To investigate the relationship between the APR-DRG severity of ill-
ness index (SOI) used to determine the reimbursement/payment level for stroke 
